WO2002022188A1 - Dialysats peritoneaux - Google Patents
Dialysats peritoneaux Download PDFInfo
- Publication number
- WO2002022188A1 WO2002022188A1 PCT/JP2001/007772 JP0107772W WO0222188A1 WO 2002022188 A1 WO2002022188 A1 WO 2002022188A1 JP 0107772 W JP0107772 W JP 0107772W WO 0222188 A1 WO0222188 A1 WO 0222188A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peritoneal
- compound
- ring
- inhibitor
- peritoneal dialysis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
Definitions
- the present invention relates to a peritoneal dialysate used for treating renal peritoneal dysfunction. More specifically, the present invention relates to a peritoneal dialysate in which protein cross-linking by a sugar osmotic agent such as glucose added to the dialysate is suppressed.
- Peritoneal dialysis is one of the effective treatments for patients with renal failure.
- a catheter is placed in the abdominal cavity of a patient with renal insufficiency, the peritoneal dialysate is infused into the peritoneal cavity from the dialysate bag through this, stored for a certain period of time, and then discharged out of the body through the catheter. Is repeated several times a day.
- the peritoneal dialysis method is different from the hemodialysis method using an artificial membrane, and since blood can be continuously and continuously purified through the peritoneum, which is the patient's own biological membrane, it is physiologically superior to the blood dialysis method. It has the advantage of easy social activities and is widely used.
- the excess water in the blood excreted by a healthy person as urine is removed between the extracorporeal blood circulation circuit and the outside of the membrane via a semipermeable membrane, as in hemodialysis. Can not be removed by a method that gives a pressure difference to the Therefore, in the peritoneal dialysis method, an osmotic agent is added to the dialysate injected into the peritoneal cavity, the osmotic pressure of the dialysate is made higher than the osmotic pressure of blood, and water is removed by ultrafiltration. . As a means to increase osmotic pressure, it is not possible to increase the electrolyte salt concentration, so that glucose has been used exclusively as an osmotic agent.
- glucose was considered to be the safest physiologically and had no metabolic problems if absorbed into the body.
- dialysate containing glucose ⁇ replacement paper (Rule 26) If peritoneal dialysis is continued for a long time using glucose, a large amount of glucose is absorbed into the body and reacts with amino acids, peptides and proteins in the body to produce AGE compounds, which will be described later. This causes cross-linking between protein molecules such as collagen, and further promotes hardening and thickening of the peritoneum, making it difficult to remove excess water in the body and forced to stop peritoneal perfusion It has been found.
- a saccharide (I) having a carbonyl group such as glucose reacts with an amino acid, a peptide, a protein or the like ( ⁇ ), and as shown in the formula (1), a Schiff base (111) or an amadrid compound (IV) After passing through the intermediate, it becomes a highly reactive compound called Advanced Glycation End Products (hereinafter referred to as AGE), which causes bonds that crosslink protein molecules.
- AGE Advanced Glycation End Products
- the above-mentioned glucose-modified product is a substance having a higher AGE-forming reactivity than saccharides, and when such a glucose-modified product is contained in the dialysate, it is several tens to several thousand times that of glucose alone.
- the cross-linking proceeds at a speed of.
- PEPTIDE one N- C one LYSINE one N- C one PEPTIDE
- the inventors of the present invention believe that since the cross-linking reaction of protein by glucose and a denatured glucose proceeds by the above mechanism, it is considered that the addition of a compound that inhibits this reaction can suppress the cross-linking reaction. As a result of searching for various additives, we found many compounds that suppress the crosslinking reaction.
- the present inventors have found a compound which has an effect of dissociating the cross-linking of a protein having a single cross-link.
- the present invention is a peritoneal dialysate obtained by adding a protein cross-linking inhibitor and / or a protein cross-linking dissociating agent to an aqueous solution in which an electrolyte salt and a saccharide osmotic agent are dissolved. Further, the present invention is a method for preparing a peritoneal dialysis solution containing the inhibitor and the Z or / protein cross-linking dissociating agent, which are sterilized without decomposing the protein cross-linking inhibitor.
- a saccharide As the osmotic agent of the peritoneal dialysate of the present invention, a saccharide is used.
- the saccharide include monosaccharides such as glucose and mannose, dibranches such as sugar cane and fructose, or oligomers, and polymers such as dextran and dextrin.
- the dialysate may contain amino acids, peptides, proteins, etc. in addition to saccharides.
- the electrolyte salt is sodium chloride, magnesium chloride, calcium chloride, A mixture of sodium lactate, sodium bicarbonate, etc., whose composition and concentration are close to serum is desirable, and blood calcium and magnesium in patients taking the drug due to concurrent disease.
- concentrations deviate from the normal values, it is preferable to use those obtained by adjusting these concentrations in the dialysate.
- the protein cross-linking inhibitor added to the aqueous solution in which the electrolyte salt and the saccharide osmotic agent are dissolved in the present invention can be inhibited at any stage of the AGE-forming reaction, and is not physiologically harmless. Either can be used. Further, a protein cross-linking dissociating agent can be used as long as it dissociates protein cross-linking in a physiological environment and its product is harmless. .
- a reducing agent or an antioxidant is effective as a bond inhibitor or a protein cross-linking dissociator.
- the reducing agent one having a low oxidation-reduction potential is effective, and in particular, a reducing agent having a potential lower than the oxidation-reduction potential (+160 mV to +180 mV) of physiological saline is effective.
- reducing agents or antioxidants and other compounds more specifically, mercapto compounds, sulfides, hydrosulfides, oxygenates of reducing sulfur, thiopereas and derivatives thereof, Cyclic compounds having a hydroxyl group and / or a carboxyl group, flavonoid compounds, nitrogen-containing heterocyclic compounds, hydrazyl group compounds or mucopolysaccharides having a peronic acid group are effective as protein cross-linking inhibitors. .
- Representative compounds exhibiting a protein cross-linking dissociation effect are thiazole derivatives.
- the mercapto compound has a mercapto 'group (one SH group), and examples thereof include cysteine, acetylcystine, mercaptoethanol, glutathione, dithioerythritol, and N-acetylmercapto succinic anhydride.
- sulfides and hydrosulfides examples include sodium sulfide, sodium hydrosulfide, etc. Is mentioned.
- Reducing sulfur oxyacid salts include sodium sulfite, bisulfite, thiosulfate, metabisulfite, or sodium, potassium nitrite, or other physiologically safe salts. These salts may be acid sulphite (bisulphite).
- Thioreas and derivatives thereof include thiorea and dimethylthiourea.
- Examples of the cyclic compound having a hydroxyl group and / or a carboxyl group include physiologically safe salts such as acetylsalicylic acid, ascorbic acid and its sodium salt.
- a compound having two or more hydroxyl groups in a heterocyclic compound is preferable, and quercetin dihydrate, catechin, epicatechin, or Examples thereof include hydrates and the like.
- a compound having a thiazole ring, a thiazoline ring, a thiazolidine ring, a triazole ring, a tetrazole ring, an indole ring, an imidazole ring, a pyridin ring, or a pyrimidine ring can be used.
- Examples of the compound having a thiazole ring include N- (2-thiazolyl) sulfanylamide (N- (2-thiazolyl) sulfani lami de) and N-phenacinolethiazole bromide.
- N-phenacylthiazole bromide is effective as a protein cross-linking dissociating agent that acts on a protein having a cross-linked bond and dissociates the cross-linking.
- examples of the compound having an indole ring include N-acetylbutytophan and the like.
- Examples of the compound having a triazole ring include 4- (1,2,3,4-thiatriazo-5-lylamino) phenol monohydrate.
- 2-mercaptothiazoline has been cited as a compound having a thiazoline ring. I can do it.
- Examples of the compound having a thiazolidine ring include 2-otaso 4-thiazolidinecarboxylic acid.
- Examples of the hydrazyl group-containing compound include aminoguanidine hydrochloride.
- Heparin can be mentioned as a mucopolysaccharide having a humic acid group.
- the addition amount of these proteins crosslinking inhibitor force s that differ depending on the type of inhibitor, sugars to 0 1-2 0 0 wt%, preferably:! 1100% by weight is preferably added. If the amount is too small, the effect of suppressing cross-linking is insufficient, and if it is too large, the solubility becomes unstable, which is not preferable.
- concentration of the saccharide osmotic agent is expressed in the unit of osmotic pressure (mOsm / 1)
- the range of the electrolyte salt solution is preferably plus 5 to 300 mOsm / 1. If the amount of saccharide osmotic agent is too small, water removal will be insufficient, and if it is too large, diabetic symptoms will worsen and many side effects will occur.
- the dialysate may contain a colloid osmotic agent in addition to the saccharide osmotic agent as the osmotic agent.
- a colloid osmotic agent a compound having a high molecular weight and exhibiting an osmotic pressure recognizable by a solution thereof is used, and albumin, globulin and the like are typically used. These are not limited to those commercially available as reagents or plasma fraction preparations, and a mixture of protein components recovered from the patient's own peritoneal dialysis effluent can also be used. In this method, as described in Japanese Patent Application No. 8-1500930 and Japanese Patent Application No. 9-132038 proposed by the inventor, they are discharged outside the body.
- the recovered peritoneal dialysis solution is concentrated using a semipermeable membrane, and then diluted by adding water or an electrolyte solution.These steps are repeated to purify the solution.
- Isoelectric focusing of proteins by deacidification by water dialysis through a membrane, separation from the supernatant, and re-dissolution in a new dialysate, which can be used as a colloid osmotic agent. it can.
- Ma Colloidal osmotic agents can be newly added. By replacing part of the saccharide osmotic agent with a non-saccharide oncotic agent, the amount of bran osmotic agent used can be reduced, thereby suppressing protein cross-linking due to the presence of saccharides. it can.
- the concentration of the colloid osmotic agent is preferably in the range of 0.1 to 3 Og / d1.
- the peritoneal dialysate of the present invention can be obtained by adding a protein cross-linking inhibitor or / and a protein cross-linking dissociator to an aqueous solution in which an electrolyte salt and a saccharide osmotic agent are dissolved, and the peritoneal dialysate is sterilized. Sterilization is usually performed at a high temperature of 110 ° C or higher, and the pH is lowered to about 5.0 to 5.8 to prevent denaturation of glucose. If a sterilization treatment is performed under such conditions after the addition of the crosslinking inhibitor, some of the inhibitors and dissociating agents are susceptible to degradation or denaturation. Before use, add an inhibitor.
- a semi-permeable membrane such as a nanofilter
- Most of the saccharide osmotic agents used in the present invention have a reducing terminal group, and are easily denatured by high-temperature sterilization treatment. If a high-temperature stable reducing agent such as sulphite, sulphite, sulphide, hydrosulphide, etc. is sterilized together with the saccharide permeation, even if the saccharide has a reducing terminal group such as glucose, the glucose denaturation reaction itself is suppressed. can do. This is more efficient than adding the inhibitor after the denatured product is formed, and this method can keep the concentration of the glucose denatured product in the dialysate below the detection limit.
- the degree of protein cross-linking is determined by measuring the intensity of fluorescence using the phenomenon of fluorescence generated by cross-linking of AGE-linked proteins. 0 (Reference: Lee KW et al "A systematic approach to evaluate the modication of lens protein by gly cat ion-induced crosslinking "Biochim. Biophys Acta: 1453 (1) 141-151 Jan. 6, 1999))
- glyoxal which is a denatured glucose product, whose AGE-promoting activity is much greater than that of glucose, was used as a model compound. It was dissolved in a phosphate buffer solution containing 5 Omg / ml, and the mercapto group-containing compound shown in Table 1 was added at 20 mM / 1, and the mixture was incubated at 37 ° C for 2 weeks.
- the fluorescence value was measured in the same manner as in Example 1 except that no inhibitor was added. Table 1 shows the results.
- Example 2 Fluorescent intensity was measured in the same manner as in Example 1 using methyldalioxal for sodium sulfite and sodium acid sulfite and sodium sulfite as a cross-linking inhibitor. I asked. Table 2 shows the results.
- Example 2 the fluorescence intensity was measured in the same manner as in Example 2 except that only methyldaryoxal was added to human albumin without adding a crosslinking inhibitor. Table 2 shows the results.
- Example 2 2-Mercaptothiazoline 48 Comparative Example 2 Control (no inhibitor added) 100 [Example 3]
- the cross-linking inhibitor was changed to acetylsalicylic acid and ascorbic acid, and the increased fluorescence relative to Comparative Example 2 was measured in the same manner as in Example 2. Table 2 shows the results.
- Example 2 The crosslinking inhibitor used in Example 2 was replaced with quercetin dihydrate, catechin hydrate and epicatechin, which were dissolved in dimethinoresulfoxide, and a phosphate buffer solution was added at a ratio of 1: 3. In the same manner as in Example 2, the relative value of the increased fluorescence value with Comparative Example 2 was measured. Table 2 shows the results.
- Example 2 the increased fluorescence value relative to Comparative Example 2 was measured in the same manner as in Example 2, except that heparin was used as the crosslinking bond inhibitor. Table 2 shows the results.
- Example 2 the increased fluorescence value relative to Comparative Example 2 was measured in the same manner as in Example 2 except that aminoguanidine hydrochloride was used as the crosslinking bond inhibitor. Table 2 shows the results.
- Example 4 the inhibitor was replaced with N-phenacylthiazolymbuide, and this was converted to a solution obtained by dissolving 20 mM / 1 in a mixed solvent of methanol and phosphate buffer 1: 1 as in Example 4. Then, the relative value of the increased fluorescence value with Comparative Example 2 was measured. Table 2 shows the results.
- Example I the inhibitor was N- (2-thiazolyl) sulfanylamide, 2-mercapto-4-methyl-5-thiazole'acetic acid, 4- (1,2,3,4-thiatriazo-1-5-linoleamino ) Phenol hydrate, 2-oxo-1.4-thiazolidine force Instead of rubonic acid and 2-mercaptothiazoline, these were dissolved in a mixed solvent of DMSO: phosphate buffer 1: 3 in 20 mM Z1 and used as a solution. In the same manner as in Example 7, the relative value of the increased fluorescence value with Comparative Example 2 was measured. Table 2 shows the results. [Example 9, Comparative Example 3]
- Example 11 N-phenacylthiazolidine ester was prepared by adding epicatechin and catechin dihydrate instead of methanol: phosphate buffer to a mixed solvent of DMSO: phosphate buffer 1: 3. Using the solution in which 0 mM / 1 was dissolved, the mixture was further incubated for 7 days in the same manner as in Example 9, the fluorescence intensity on the 14th day was measured, and the decrease from the fluorescence intensity on the 7th day was determined. Table 5 shows the results. [Table 5]
- a 7-week-old rat (body weight: 300 ⁇ 15 ⁇ ) was intraperitoneally injected with the solution (A) listed in Table 6 at a rate of 15 ml / day for 5 days, and the peritoneal peritoneum was collected and frozen. The sections were treated with the AGE antibody and the color development was observed. The results are shown in Table 7 c [Table 6]
- a solution (B) was prepared by adding methyldaryoxal to the mixed solution (A) used in Comparative Example 5, and the color development state of the rat peritoneal section with the AGE antibody was observed in the same manner as in Comparative Example 5.
- Table 7 shows the results.
- Example 14 After the same experiment as in Comparative Example 6 was continued for 5 days, the peritoneal cavity of this rat was repeatedly washed with the solution (A), and then the solution (A) was added to the N-phenacylthiazolidine buffer 20 mM / The solution (D) to which 1 was added was continuously injected at 15 ⁇ 1 for 5 days every day, and a rat peritoneal section was subjected to an AGE antibody staining test in the same manner as in Comparative Example 3. Table 7 shows the results.
- Peritoneal dialysis is an excellent method for treating renal failure because it is physiologically superior and facilitates social activities for patients. Since excess water is removed by the osmotic pressure generated by adding an osmotic agent to the eluate, a cross-linking reaction of the protein occurs due to the osmotic agent, dalkose or a modified dulose, and peritoneal dialysis is performed due to hardening of the peritoneum. There is a problem that you cannot continue. According to the present invention, a compound that inhibits a cross-linking reaction is added to a peritoneal dialysate, thereby suppressing a protein cross-linking reaction and dissociating a cross-link once formed.
- peritoneal dialysis treatment can be performed for a long period of time without causing peritoneal sclerosis, and even if the peritoneum is already hardening to some extent, it returns to a normal state and the water removal ability is improved. Can supply dialysate to recover. Therefore, the present invention is extremely useful as a means for continuously performing treatment by peritoneal dialysis without any trouble.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020037003487A KR100819409B1 (ko) | 2000-09-13 | 2001-09-07 | 복막 투석액 및 그 제조법 |
US10/380,350 US20040096845A1 (en) | 2000-09-13 | 2001-09-07 | Peritoneal dialysates |
AT01963506T ATE556730T1 (de) | 2000-09-13 | 2001-09-07 | Peritoneal-dialysate |
EP01963506A EP1323440B1 (en) | 2000-09-13 | 2001-09-07 | Peritoneal dialysates |
CA2422346A CA2422346C (en) | 2000-09-13 | 2001-09-07 | Dialysate of peritoneal dialysis and its preparation method |
US11/704,931 US20070199898A1 (en) | 2000-09-13 | 2007-02-12 | Dialysate of peritoneal dialysis and its preparation method |
US12/662,907 US8216776B2 (en) | 2000-09-13 | 2010-05-11 | Dialysate of peritoneal dialysis and its preparation method |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-277810 | 2000-09-13 | ||
JP2000277810 | 2000-09-13 | ||
JP2001-40718 | 2001-02-16 | ||
JP2001040718 | 2001-02-16 | ||
JP2001-186642 | 2001-06-20 | ||
JP2001186642A JP4882054B2 (ja) | 2000-09-13 | 2001-06-20 | 腹膜透析液およびその調製法 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10380350 A-371-Of-International | 2001-09-07 | ||
US11/704,931 Division US20070199898A1 (en) | 2000-09-13 | 2007-02-12 | Dialysate of peritoneal dialysis and its preparation method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002022188A1 true WO2002022188A1 (fr) | 2002-03-21 |
Family
ID=27344611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/007772 WO2002022188A1 (fr) | 2000-09-13 | 2001-09-07 | Dialysats peritoneaux |
Country Status (8)
Country | Link |
---|---|
US (3) | US20040096845A1 (ja) |
EP (1) | EP1323440B1 (ja) |
JP (1) | JP4882054B2 (ja) |
KR (1) | KR100819409B1 (ja) |
CN (1) | CN1232261C (ja) |
AT (1) | ATE556730T1 (ja) |
CA (1) | CA2422346C (ja) |
WO (1) | WO2002022188A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008513493A (ja) * | 2004-09-21 | 2008-05-01 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | 腎臓透析を受ける患者を治療するための方法及び組成物 |
WO2009152070A2 (en) * | 2008-06-09 | 2009-12-17 | Anupkumar Shetty | Intradialytic administration of sodium thiosulfate |
US11160766B2 (en) | 2015-07-20 | 2021-11-02 | Opterion Health Ag | Peritoneal therapeutic fluid |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001231154A1 (en) | 2000-01-24 | 2001-07-31 | Adherex Technologies Inc. | Peptidomimetic modulators of cell adhesion |
AU2006236150A1 (en) | 2005-04-20 | 2006-10-26 | Fred Hutchinson Cancer Research Center | Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms |
US20070155672A1 (en) * | 2006-01-05 | 2007-07-05 | Markus Voges | Sterilized peritoneal dialysis solutions containing heparin |
US8715221B2 (en) * | 2006-03-08 | 2014-05-06 | Fresenius Medical Care Holdings, Inc. | Wearable kidney |
BG66222B1 (bg) * | 2006-06-08 | 2012-06-29 | "Унифарм" Ад | Диализен състав |
MX2011004631A (es) * | 2008-11-03 | 2011-06-17 | Fresenius Med Care Hldg Inc | Sistema de dialisis peritoneal portatil. |
US20100183748A1 (en) * | 2009-01-21 | 2010-07-22 | Ikaria, Inc. | Methods for Treating or Preventing Radiocontrast Agent Induced Kidney Injury |
MX354635B (es) * | 2009-09-08 | 2018-03-14 | Fresenius Medical Care Holdings Inc | Sistema de diálisis peritoneal. |
CN101890041B (zh) * | 2010-02-10 | 2012-07-25 | 上海蓝怡科技有限公司 | 腹膜透析液及其制备方法 |
JP2011241174A (ja) * | 2010-05-18 | 2011-12-01 | Jms Co Ltd | アミロイド形成抑制物質を含有する溶液組成物 |
WO2014091002A1 (en) | 2012-12-14 | 2014-06-19 | Gambro Lundia Ab | Cleaning of biological fluid |
CN104666337A (zh) * | 2013-11-27 | 2015-06-03 | 天津金耀集团有限公司 | 一种腹膜透析液(乳酸盐)(低钙)组合物 |
CN104666336A (zh) * | 2013-11-27 | 2015-06-03 | 天津金耀集团有限公司 | 腹膜透析液(乳酸盐)(低钙)组合物 |
CN104666335A (zh) * | 2013-11-27 | 2015-06-03 | 天津金耀集团有限公司 | 一种腹膜透析液(乳酸盐)(低钙)组合物的制备方法 |
CN104666339A (zh) * | 2013-11-27 | 2015-06-03 | 天津金耀集团有限公司 | 腹膜透析液(乳酸盐)(低钙)组合物的制备方法 |
CN104666331A (zh) * | 2013-11-27 | 2015-06-03 | 天津金耀集团有限公司 | 一种腹膜透析液(乳酸盐)组合物 |
IL264725B2 (en) | 2016-08-11 | 2023-03-01 | Sulfilatec Inc | Preparations and methods for treating the disease |
US20190183927A1 (en) * | 2016-08-11 | 2019-06-20 | Sulfilatec, Inc. | Medical and nutritional compositions and methods of use |
AU2018231072B2 (en) * | 2017-03-08 | 2024-04-04 | Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals | Intradialytic use of sodium thiosulfate |
AU2018231016B2 (en) | 2017-03-08 | 2024-03-07 | Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals | Intradialytic use of sodium nitrite |
CN108310005A (zh) * | 2018-04-18 | 2018-07-24 | 浙江天瑞药业有限公司 | 一种抗腹膜纤维化的腹膜透析液 |
WO2020203086A1 (ja) | 2019-03-29 | 2020-10-08 | 国立大学法人香川大学 | D-アロースおよび/またはd-アルロースを含有してなる腹膜透析液の浸透圧調整剤 |
ES2958165A1 (es) * | 2022-07-05 | 2024-02-02 | Consejo Superior Investigacion | Soluciones para diálisis peritoneal que contienen un flavonoide natural como agente osmótico |
CN115624566B (zh) * | 2022-12-22 | 2023-03-10 | 广东省人民医院 | 一种腹膜透析液及其制备方法和应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07136255A (ja) * | 1993-11-19 | 1995-05-30 | Nippon Oil & Fats Co Ltd | 血液透析回路用組成物及び血液透析回路用チャンバー |
JPH08150930A (ja) | 1994-11-30 | 1996-06-11 | Central Japan Railway Co | 鉄道車両における車体 |
JPH08337590A (ja) * | 1995-06-15 | 1996-12-24 | Terumo Corp | 腹膜保護成分およびそれを含有した腹膜透析液 |
JPH09302388A (ja) | 1996-05-10 | 1997-11-25 | Olympus Optical Co Ltd | 洗浄剤組成物および洗浄方法 |
WO2000010606A1 (fr) * | 1998-08-24 | 2000-03-02 | Kurokawa, Kiyoshi | Medicaments de sedation de l'agression du carbonyle et des dialysats peritoneaux |
WO2000020052A1 (fr) * | 1998-10-07 | 2000-04-13 | Asahi Sakai | Dispositif et methode de perfusion de fluide de dialyse peritoneale |
WO2001089478A1 (en) | 2000-05-25 | 2001-11-29 | Gambro Lundia Ab | Carbohydrate medical solution and sulphite stabilisator in a multiple compartment container and use thereof |
WO2002053094A2 (en) | 2000-12-28 | 2002-07-11 | Gambro Lundia Ab | Method for detoxifying a carbohydrate containing solution |
JP5058604B2 (ja) * | 2004-01-28 | 2012-10-24 | スミス アンド ネフュー インコーポレーテッド | 縫合用の装填 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3617451A (en) * | 1969-06-10 | 1971-11-02 | Macdermid Inc | Thiosulfate copper plating |
US4100098A (en) * | 1976-10-26 | 1978-07-11 | Olin Corporation | Stabilized solutions of sodium dithionite |
US6248726B1 (en) * | 1985-06-22 | 2001-06-19 | M L Laboratories Plc | Method of peritoneal dialysis using glucose polymer solutions |
DE3620845A1 (de) | 1986-06-21 | 1987-12-23 | Dieter Von Dr Horsten | Infusionsloesung |
DE3721545A1 (de) * | 1986-07-03 | 1988-01-07 | Takeda Chemical Industries Ltd | Badepraeparat |
JP3207886B2 (ja) | 1991-08-30 | 2001-09-10 | 科学技術振興事業団 | 金属酸化物薄膜の製造方法 |
US5610170A (en) * | 1993-01-22 | 1997-03-11 | Otsuka Pharmaceutical Factory, Inc. | Package form for bicarbonate-containing powdery pharmaceutical compositions and a method of stabilizing the compositions |
JPH09327511A (ja) | 1996-06-12 | 1997-12-22 | A S A Sangyo Kk | 腹膜透析液の回収・再生方法並びにそのための処理装置及び付属器具 |
JP2000154200A (ja) * | 1998-11-20 | 2000-06-06 | Kanegafuchi Chem Ind Co Ltd | 化合物の固定化方法 |
-
2001
- 2001-06-20 JP JP2001186642A patent/JP4882054B2/ja not_active Expired - Fee Related
- 2001-09-07 WO PCT/JP2001/007772 patent/WO2002022188A1/ja active Application Filing
- 2001-09-07 US US10/380,350 patent/US20040096845A1/en not_active Abandoned
- 2001-09-07 KR KR1020037003487A patent/KR100819409B1/ko not_active IP Right Cessation
- 2001-09-07 AT AT01963506T patent/ATE556730T1/de active
- 2001-09-07 CN CNB01815509XA patent/CN1232261C/zh not_active Expired - Fee Related
- 2001-09-07 EP EP01963506A patent/EP1323440B1/en not_active Expired - Lifetime
- 2001-09-07 CA CA2422346A patent/CA2422346C/en not_active Expired - Fee Related
-
2007
- 2007-02-12 US US11/704,931 patent/US20070199898A1/en not_active Abandoned
-
2010
- 2010-05-11 US US12/662,907 patent/US8216776B2/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07136255A (ja) * | 1993-11-19 | 1995-05-30 | Nippon Oil & Fats Co Ltd | 血液透析回路用組成物及び血液透析回路用チャンバー |
JPH08150930A (ja) | 1994-11-30 | 1996-06-11 | Central Japan Railway Co | 鉄道車両における車体 |
JPH08337590A (ja) * | 1995-06-15 | 1996-12-24 | Terumo Corp | 腹膜保護成分およびそれを含有した腹膜透析液 |
JPH09302388A (ja) | 1996-05-10 | 1997-11-25 | Olympus Optical Co Ltd | 洗浄剤組成物および洗浄方法 |
WO2000010606A1 (fr) * | 1998-08-24 | 2000-03-02 | Kurokawa, Kiyoshi | Medicaments de sedation de l'agression du carbonyle et des dialysats peritoneaux |
WO2000020052A1 (fr) * | 1998-10-07 | 2000-04-13 | Asahi Sakai | Dispositif et methode de perfusion de fluide de dialyse peritoneale |
WO2001089478A1 (en) | 2000-05-25 | 2001-11-29 | Gambro Lundia Ab | Carbohydrate medical solution and sulphite stabilisator in a multiple compartment container and use thereof |
WO2002053094A2 (en) | 2000-12-28 | 2002-07-11 | Gambro Lundia Ab | Method for detoxifying a carbohydrate containing solution |
JP5058604B2 (ja) * | 2004-01-28 | 2012-10-24 | スミス アンド ネフュー インコーポレーテッド | 縫合用の装填 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008513493A (ja) * | 2004-09-21 | 2008-05-01 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | 腎臓透析を受ける患者を治療するための方法及び組成物 |
WO2009152070A2 (en) * | 2008-06-09 | 2009-12-17 | Anupkumar Shetty | Intradialytic administration of sodium thiosulfate |
WO2009152070A3 (en) * | 2008-06-09 | 2010-03-04 | Anupkumar Shetty | Intradialytic administration of sodium thiosulfate |
US11160766B2 (en) | 2015-07-20 | 2021-11-02 | Opterion Health Ag | Peritoneal therapeutic fluid |
Also Published As
Publication number | Publication date |
---|---|
EP1323440A4 (en) | 2004-02-04 |
US8216776B2 (en) | 2012-07-10 |
KR20030040450A (ko) | 2003-05-22 |
ATE556730T1 (de) | 2012-05-15 |
KR100819409B1 (ko) | 2008-04-07 |
CA2422346C (en) | 2011-11-08 |
EP1323440B1 (en) | 2012-05-09 |
JP4882054B2 (ja) | 2012-02-22 |
JP2002315825A (ja) | 2002-10-29 |
CN1232261C (zh) | 2005-12-21 |
CN1458850A (zh) | 2003-11-26 |
US20040096845A1 (en) | 2004-05-20 |
EP1323440A1 (en) | 2003-07-02 |
US20070199898A1 (en) | 2007-08-30 |
US20100221147A1 (en) | 2010-09-02 |
CA2422346A1 (en) | 2003-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002022188A1 (fr) | Dialysats peritoneaux | |
JP2002315825A5 (ja) | ||
KR100478181B1 (ko) | 카르보닐 스트레스상태 개선제 및 복막투석액 | |
EP0958832B1 (en) | Albumin containing peritoneal dialysis fluid | |
JP5690040B2 (ja) | 重炭酸塩ベースの腹膜透析溶液 | |
US5092838A (en) | Histidine buffered peritoneal dialysis solution | |
JP3262620B2 (ja) | 腹膜炎によって生ずる傷害および生理学的副作用を最小にするために使用し得る腹膜透析液 | |
KR100778611B1 (ko) | 복막투석용 조성물 | |
WO2001002004A1 (en) | Peritoneal dialysis solution containing antioxidant for treating renal failure | |
KR20080020600A (ko) | 복막 투석 유체 | |
US8545893B2 (en) | Keratin biomaterials for treatment of ischemia | |
JP2006305345A (ja) | カルボニルストレス状態改善剤、および腹膜透析液 | |
JP4061775B2 (ja) | アルブミン含有腹膜透析液 | |
KR20220028198A (ko) | 투석액 및 그 제조방법 | |
JP2009269887A (ja) | 希少糖を含有する腹膜劣化抑制剤、腹膜透析液および腹膜透析法 | |
JPH0871146A (ja) | シクロデキストリン又はその誘導体を含有する腹膜透析液 | |
CA2102234C (en) | Peritoneal dialysis composition and method usable during and after peritonitis | |
JP2021006262A (ja) | 透析装置、アクセプター薬剤、ドナー薬剤、リンス液およびリンス液としての使用方法 | |
JP2004016615A (ja) | 晶質浸透圧剤及び膠質浸透圧剤を含有する腹膜透析液 | |
JP2004283571A (ja) | 三分割法による腹膜透析液調製法 | |
CN114619041B (zh) | 一种铈修饰金纳米团簇及其制备方法、应用 | |
CN107281196A (zh) | 一种含有薁磺酸及其盐的低钙乳酸盐腹膜透析液药物组合物 | |
JPWO2002047677A1 (ja) | カルボニルストレスの改善剤 | |
CN1669553A (zh) | 硫普罗宁注射液及其制备方法 | |
CA2626680A1 (en) | Peritoneal dialysis composition and method usable during and after peritonitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020037003487 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2422346 Country of ref document: CA Ref document number: 01815509X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10380350 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001963506 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037003487 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001963506 Country of ref document: EP |